Ascendis Pharma shares are trading lower after the company announced it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. Also, Raymond James downgraded the stock from Strong Buy to Outperform.

Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel Growth

The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.

Ascendis Pharma Supports IpoparaTour Awareness Initiative in Italy

Ascendis Pharma is providing non-conditional support for the IpoparaTour, a series of territorial events in Italy aimed at raising awareness for hypoparathyroidism.

Ascendis Pharma to Report Third Quarter 2026 Financial Results on November 12, 2026

Ascendis Pharma announced it will release its third quarter 2026 financial results and provide a business update on November 12, 2026.

Ascendis Pharma Announces Positive Long-Term Data for TransCon PTH in Hypoparathyroidism

Ascendis Pharma reported new data from its Phase 2 and Phase 3 trials showing that TransCon PTH provides sustained, clinically meaningful improvements in kidney function for adults with hypoparathyroidism.

Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia

Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization

BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed